Hospital
Seventh-Day Adventists Loma Linda University Medical Center
Seventh-Day Adventists Loma Linda University Medical Center was paid $2.13M by Medicaid between Jan 2018 and Nov 2024, across 120 billing codes. Its largest line is Z7502, — 27% of everything it billed.
33Billing provider infoSEVENTH-DAY ADVENTISTS LOMA LINDA UNIVERSITY MEDICAL CENTER
LOMA LINDA, CA 92354
LOMA LINDA, CA 92354
33aNPI1841207750assigned 08/02/2006
33bProvider typeRehabilitation Hospital Unit
28Total paid$2.13M
24GClaims96,957
24DCodes billed120
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other Rehabilitation Hospital Unit providers in California
Rank by total paid#10 of 22
Median peer was paid$308K
This provider vs. median6.9×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 27,232 | $553K | |
| 2019 | 27,849 | $549K | |
| 2020 | 19,731 | $455K | |
| 2021 | 7,764 | $211K | |
| 2022 | 3,361 | $53K | |
| 2023 | 6,588 | $152K | |
| 2024incomplete | 4,432 | $162K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| Z7502 | 27% | 15,028 | 14,893 | $580K | |
| 80053 | Comprehensive metabolic panel | 8.9% | 12,839 | 11,959 | $189K |
| 83970 | 5.7% | 2,109 | 1,987 | $123K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 5.4% | 311 | 283 | $115K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | 4.9% | 103 | 82 | $104K |
| Z7506 | 4.8% | 779 | 777 | $102K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 4.2% | 8,094 | 7,735 | $89K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 3.8% | 997 | 972 | $81K |
| X4304 | 2.9% | 1,921 | 848 | $62K | |
| Z7610 | 2.4% | 5,301 | 2,648 | $51K | |
| 83735 | 1.9% | 4,347 | 3,847 | $41K | |
| 84100 | 1.5% | 5,289 | 4,839 | $33K |
108 more codes
| 80197 | 1.5% | 1,670 | $32K | |
| 82570 | 1.5% | 4,321 | $31K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 1.4% | 1,055 | $30K |
| X3908 | 1.4% | 992 | $30K | |
| 87799 | 1.3% | 488 | $28K | |
| 93531 | 1.2% | 12 | $26K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.2% | 310 | $25K |
| 84443 | Thyroid stimulating hormone (TSH) | 1.0% | 930 | $22K |
| Z7508 | <1% | 349 | $20K | |
| 86140 | <1% | 2,694 | $20K | |
| 81001 | <1% | 4,067 | $18K | |
| Z7500 | <1% | 526 | $18K | |
| 86235 | <1% | 594 | $14K | |
| Z7512 | <1% | 528 | $14K | |
| 86160 | <1% | 641 | $13K | |
| 86480 | <1% | 228 | $13K | |
| X4301 | <1% | 135 | $13K | |
| 84156 | <1% | 3,651 | $13K | |
| 85027 | <1% | 1,392 | $13K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 758 | $10K |
| 85652 | <1% | 2,635 | $10K | |
| 87070 | <1% | 834 | $10K | |
| 83880 | <1% | 270 | $9K | |
| 84439 | <1% | 603 | $8K | |
| 82977 | <1% | 677 | $7K | |
| 86039 | <1% | 433 | $6K | |
| 80061 | Lipid panel | <1% | 309 | $6K |
| 83615 | <1% | 684 | $5K | |
| X3910 | <1% | 401 | $5K | |
| 82248 | <1% | 706 | $5K | |
| 82610 | <1% | 310 | $5K | |
| X3920 | <1% | 99 | $5K | |
| X3922 | <1% | 97 | $4K | |
| 84550 | <1% | 714 | $4K | |
| 93325 | <1% | 38 | $4K | |
| 87205 | <1% | 616 | $4K | |
| 84478 | <1% | 472 | $4K | |
| 86923 | <1% | 78 | $4K | |
| 82330 | <1% | 180 | $3K | |
| 82465 | <1% | 481 | $3K | |
| 87497 | <1% | 47 | $3K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 424 | $3K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 50 | $3K |
| 84305 | <1% | 103 | $2K | |
| 82728 | <1% | 119 | $2K | |
| 82805 | <1% | 56 | $2K | |
| Z7510 | <1% | 26 | $2K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 407 | $2K |
| 82550 | <1% | 230 | $2K | |
| 86706 | <1% | 124 | $2K | |
| 87340 | <1% | 120 | $2K | |
| 76937 | <1% | 101 | $2K | |
| J2704 | Injection, propofol, 10 mg | <1% | 247 | $2K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 30 | $1K |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | <1% | 46 | $1K |
| 84255 | <1% | 40 | $1K | |
| 83550 | <1% | 112 | $1K | |
| 54640 | <1% | 12 | $1K | |
| 86376 | <1% | 52 | $1K | |
| 14040 | <1% | 13 | $913.77 | |
| 84630 | <1% | 59 | $899.73 | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 31 | $794.90 |
| 86225 | <1% | 40 | $764.05 | |
| 71045 | Radiologic examination, chest; single view | <1% | 78 | $758.16 |
| 85610 | <1% | 132 | $727.74 | |
| 86833 | <1% | 59 | $654.31 | |
| 86832 | <1% | 58 | $643.22 | |
| 84590 | <1% | 53 | $641.30 | |
| 82108 | <1% | 32 | $639.68 | |
| X4102 | <1% | 12 | $562.12 | |
| 86803 | <1% | 27 | $545.94 | |
| 82435 | <1% | 86 | $539.66 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 103 | $490.19 |
| 84295 | <1% | 68 | $458.92 | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 14 | $417.76 |
| 83516 | <1% | 25 | $415.07 | |
| 71020 | <1% | 16 | $381.60 | |
| 85347 | <1% | 35 | $373.86 | |
| 00000 | <1% | 14 | $365.82 | |
| 85018 | <1% | 58 | $365.15 | |
| 87040 | <1% | 25 | $354.75 | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 28 | $335.44 |
| 85240 | <1% | 12 | $304.32 | |
| 86635 | <1% | 18 | $292.50 | |
| 83520 | <1% | 16 | $274.46 | |
| 87088 | <1% | 29 | $271.51 | |
| 86800 | <1% | 12 | $261.93 | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 13 | $235.82 |
| 84681 | <1% | 30 | $229.50 | |
| 84460 | <1% | 28 | $210.00 | |
| 84484 | <1% | 14 | $209.10 | |
| 86850 | <1% | 15 | $205.56 | |
| 86255 | <1% | 12 | $200.67 | |
| 84132 | <1% | 28 | $182.28 | |
| 82947 | <1% | 31 | $162.95 | |
| 82085 | <1% | 12 | $162.00 | |
| 82784 | <1% | 12 | $147.82 | |
| 84450 | <1% | 15 | $109.95 | |
| 82247 | <1% | 15 | $106.50 | |
| 82374 | <1% | 15 | $103.95 | |
| 85046 | <1% | 13 | $102.70 | |
| 87077 | <1% | 12 | $99.32 | |
| J7042 | 5% dextrose/normal saline (500 ml = 1 unit) | <1% | 13 | $89.18 |
| 82962 | <1% | 21 | $79.68 | |
| 86901 | <1% | 15 | $63.45 | |
| 86900 | <1% | 15 | $63.45 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 21 | $59.10 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 12 | $56.41 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialHILLIARD, ANTHONY (CEO)
| Provider | Location | Paid |
|---|---|---|
| Loma Linda University Children's Hospital | Loma Linda, CA | $107.10M |
| Loma Linda University Medical Center-Murrieta | Murrieta, CA | $70.86M |
| Seventh-Day Adventists Loma Linda University Medical Center | Redlands, CA | $19.31M |
| Seventh-Day Adventists Loma Linda University Medical Center | Loma Linda, CA | $13.94M |
| Seventh-Day Adventists Loma Linda University Medical Center | Loma Linda, CA | $227K |
| Loma Linda University Children's Hospital | Loma Linda, CA | $194K |
| Seventh-Day Adventists Loma Linda University Medical Center | Loma Linda, CA | $4K |
| Seventh-Day Adventists Loma Linda University Medical Center | Loma Linda, CA | $3K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.